| All Races |  |  | White |  |  | Black |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Rate ${ }^{\text {b }}$ | APC ${ }^{\text {C }}$ |  | Rate ${ }^{\text {b }}$ | $\mathrm{APC}^{C}$ |  | Rate ${ }^{\text {b }}$ | $\mathrm{APC}^{\mathrm{C}}$ |
| All Sites | $\frac{2006-2010}{176.4}$ | $\frac{2001-2010}{-1.5 *}$ | All Sites | $\frac{2006-2010}{175.8}$ | $\frac{2001-2010}{-1.4 *}$ | All Sites | $\frac{2006-2010}{210.3}$ | $\frac{2001-2010}{-2.1^{*}}$ |
| Lung and Bronchus | 49.5 | -1.7* | Lung and Bronchus | 50.2 | -1.6* | Lung and Bronchus | 53.5 | -2.4* |
| Colon and Rectum | 16.4 | -2.9* | Colon and Rectum | 15.9 | -3.0* | Colon and Rectum | 22.8 | -2.8* |
| Breast | 12.7 | -2.2* | Breast | 12.3 | -2.2* | Breast | 18.2 | -1.7* |
| Pancreas | 10.9 | 0.5* | Pancreas | 10.8 | 0.6* | Prostate ${ }^{\text {f }}$ | 18.0 | -3.4* |
| Prostate ${ }^{\text {f }}$ | 9.0 | -2.7* | Prostate ${ }^{\text {f }}$ | 8.3 | -2.5* | Pancreas | 13.7 | -0.1 |
| Leukemia | 7.1 | -1.0* | Leukemia | 7.3 | -0.9* | Liver \& IBD ${ }^{\text {g }}$ | 7.4 | 2.4* |
| Non-Hodgkin Lymphoma | 6.4 | -2.8* | Non-Hodgkin Lymphoma | 6.7 | -2.7* | Stomach | 6.7 | -3.2* |
| Liver \& $1 \mathrm{BD}^{\text {g }}$ | 5.6 | 2.4* | Liver \& IBD ${ }^{\text {g }}$ | 5.2 | 2.5* | Myeloma | 6.4 | -1.7* |
| Ovary ${ }^{\text {f }}$ | 4.5 | -2.0* | Ovary ${ }^{\text {f }}$ | 4.7 | -2.0* | Leukemia | 6.1 | -1.6* |
| Urinary Bladder | 4.4 | 0.1 | Brain and ONS ${ }^{\text {g }}$ | 4.6 | -0.4 | Non-Hodgkin Lymphoma | 4.6 | -2.5* |
| Esophagus | 4.3 | -0.6* | Urinary Bladder | 4.6 | $0.3 *$ | Esophagus | 4.4 | -4.8* |
| Brain and ONS ${ }^{\text {g }}$ | 4.3 | -0.5* | Esophagus | 4.4 | 0.0 | Corpus and Uterus, NOS ${ }^{\ddagger}$ | 4.4 | 0.4 |
| Kidney and Renal Pelvis | 4.0 | -1.0* | Kidney and Renal Pelvis | 4.1 | -1.0* | Ovary ${ }^{\text {f }}$ | 4.0 | -1.9* |
| Stomach | 3.5 | -2.9* | Myeloma | 3.1 | -1.8* | Kidney and Renal Pelvis | 3.9 | -1.1* |
| Myeloma | 3.4 | -1.8* | Melanoma of the Skin | 3.1 | $0.7 *$ | Urinary Bladder | 3.7 | -0.8 |
| Asian/Pacific Islander |  |  | American Indian/Alaska Native ${ }^{\text {d }}$ |  |  | Hispanic ${ }^{\text {e }}$ |  |  |
|  | Rate ${ }^{\text {b }}$ | $\mathrm{APC}^{\text {c }}$ |  | Rate ${ }^{\text {b }}$ | $A^{\text {APC }}{ }^{\text {c }}$ |  | Rate ${ }^{\text {b }}$ | APC $^{\text {c }}$ |
|  | 2006-2010 | 2001-2010 |  | 2006-2010 | 2001-2010 |  | 2006-2010 | 2001-2010 |
| All Sites | 108.8 | -1.2* | All Sites | 160.4 | -0.7* | All Sites | 121.8 | -1.4* |
| Lung and Bronchus | 25.5 | -1.2* | Lung and Bronchus | 40.2 | -0.7 | Lung and Bronchus | 21.3 | -2.1* |
| Colon and Rectum | 11.2 | -1.9* | Colon and Rectum | 16.9 | -0.4 | Colon and Rectum | 12.7 | -1.7* |
| Liver \& $1 B^{\text {d }}$ | 9.7 | -1.2* | Liver \& $1 B^{\text {g }}$ | 9.3 | 1.5 | Pancreas | 8.6 | 0.2 |
| Pancreas | 7.6 | 0.5 | Pancreas | 9.2 | 2.1 | Liver \& IBD ${ }^{\text {g }}$ | 8.5 | 1.6* |
| Stomach | 6.6 | $-3.4 *$ | Breast | 8.8 | -1.3 | Breast | 8.2 | -1.6* |
| Breast | 6.5 | -1.5* | Prostate ${ }^{\text {f }}$ | 8.1 | -1.0 | Prostate ${ }^{\text {f }}$ | 7.5 | -2.6* |
| Non-Hodgkin Lymphoma | 4.1 | -2.1* | Kidney and Renal Pelvis | 6.7 | -0.2 | Stomach | 5.7 | -2.7* |
| Prostat ${ }^{\text {f }}$ | 4.1 | -2.5* | Stomach | 5.6 | -5.4* | Non-Hodgkin Lymphoma | 5.3 | -1.4* |
| Leukemia | 3.9 | 0.2 | Non-Hodgkin Lymphoma | 4.8 | -3.0 | Leukemia | 4.9 | -0.9* |
| Ovary ${ }^{\text {f }}$ | 2.7 | -0.5 | Leukemia | 4.8 | -0.1 | Kidney and Renal Pelvis | 3.5 | -1.0 |
| Kidney and Renal Pelvis | 2.0 | 1.9 | Ovary ${ }^{\text {f }}$ | 4.1 | -2.3 | Ovary ${ }^{\ddagger}$ | 3.3 | -1.3* |
| Oral Cavity and Pharynx | 2.0 | -2.5* | Esophagus | 3.6 | -2.0* | Myeloma | 2.8 | -2.0* |
| Brain and ONS ${ }^{\text {g }}$ | 1.9 | -0.1 | Myeloma | 2.9 | -5.0* | Brain and ONS ${ }^{\text {g }}$ | 2.8 | -0.2 |
| Esophagus | 1.8 | -0.8 | Brain and ONS ${ }^{\text {g }}$ | 2.6 | 2.8 | Urinary Bladder | 2.4 | -1.1 |
| Myeloma | 1.7 | 0.4 | Urinary Bladder | 2.4 | 2.8 | Esophagus | 2.3 | -0.7 |

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
Top 15 cancer sites selected based on 2006-2010 age-adjusted rates for the race/ethnic group.
Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). The APC is the Annual Percent Change over the time interval.
Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. The 2006-2010 Hispanic death rates do not include deaths from the District of Columbia, North Dakota and South Carolina. The 2001-2010 Hispanic mortality trends do not include deaths from the District of Columbia, Minnesota, New Hampshire, North Dakota and South Carolina.
The rates for sex-specific cancer sites are calculated using the population for both sexes combined.
IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
The APC is significantly different from zero ( $p<.05$ ).
Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

| All Races |  |  | White |  | Black |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { Rate }^{b} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \\ \hline \end{gathered}$ |  | $\begin{array}{cc} \text { Rate }^{\mathrm{b}} & \text { APC }^{\text {c }} \\ 2006-2010 & \underline{2001-2010} \\ \hline \end{array}$ |  | $\begin{gathered} \text { Rate }^{\text {b }} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \\ \hline \end{gathered}$ |
| All Sites | 215.3 | -1.8* | All Sites | 213.1 -1.7* | All Sites | 276.6 | -2.6* |
| Lung and Bronchus | 63.5 | $-2.5 *$ | Lung and Bronchus | $63.2-2.4 *$ | Lung and Bronchus | 78.5 | -3.3* |
| Prostate | 23.0 | -3.4 * | Prostate | $21.2-3.3 *$ | Prostate | 50.9 | -3.8* |
| Colon and Rectum | 19.6 | -3.0* | Colon and Rectum | 19.1 -3.1* | Colon and Rectum | 28.7 | -2.4* |
| Pancreas | 12.5 | $0.4 *$ | Pancreas | 12.5 0.5* | Pancreas | 15.3 | 0.0 |
| Leukemia | 9.5 | -1.0* | Leukemia | $9.8-0.9 *$ | Liver \& IBD ${ }^{\text {f }}$ | 11.8 | 3.0* |
| Liver \& $I B^{\text {f }}$ | 8.3 | 2.5* | Non-Hodgkin Lymphoma | 8.5 -2.6* | Stomach | 9.8 | -3.1* |
| Non-Hodgkin Lymphoma | 8.2 | -2.6* | Urinary Bladder | 8.10 .2 | Leukemia | 8.2 | -1.3* |
| Urinary Bladder | 7.7 | 0.1 | Esophagus | 7.80 .1 | Myeloma | 7.9 | -1.3* |
| Esophagus | 7.6 | -0.5* | Liver \& $\mathrm{IBD}^{\text {f }}$ | 7.6 2.6* | Esophagus | 7.7 | -4.6* |
| Kidney and Renal Pelvis | 5.8 | -1.0* | Kidney and Renal Pelvis | $5.9-1.0 *$ | Non-Hodgkin Lymphoma | 5.9 | -2.0* |
| Brain and ONS ${ }^{\text {f }}$ | 5.2 | -0.5* | Brain and ONS ${ }^{\text {f }}$ | $5.6-0.4$ | Kidney and Renal Pelvis | 5.7 | -1.3* |
| Stomach | 4.9 | -3.2 * | Melanoma of the Skin | $4.61 .0 *$ | Urinary Bladder | 5.5 | 0.0 |
| Myeloma | 4.3 | -1.4* | Stomach | $4.2-3.4 *$ | Oral Cavity and Pharynx | 5.2 | -4.1* |
| Melanoma of the Skin | 4.1 | $0.9 *$ | Myeloma | 4.0 -1.5* | Larynx | 3.9 | -4.0* |
| Oral Cavity and Pharynx | 3.8 | -1.3* | Oral Cavity and Pharynx | 3.6 -0.8* | Brain and ONS ${ }^{\ddagger}$ | 3.0 | -0.8 |
| Asian/Pacific Islander |  |  | American Indian/Alaska Native ${ }^{\text {d }}$ |  | Hispanic ${ }^{\text {e }}$ |  |  |
|  | $\begin{gathered} \text { Rate }^{\text {b }} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \\ \hline \end{gathered}$ |  | $\begin{array}{cc} \text { Rate }^{\text {b }} & \text { APC }^{\text {c }} \\ 2006-2010 & 2001-2010 \\ \hline \end{array}$ |  | $\begin{gathered} \text { Rate }^{\text {b }} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \\ \hline \end{gathered}$ |
| All Sites | 132.4 | -1.3* | All Sites | $191.0 \quad-0.4$ | All Sites | 152.1 | -1.6* |
| Lung and Bronchus | 35.5 | -1.6* | Lung and Bronchus | $49.6-0.5$ | Lung and Bronchus | 31.3 | -2.8* |
| Liver \& $1 B^{\text {f }}$ | 14.4 | -1.0* | Prostate | $20.7-1.4$ | Prostate | 19.2 | -3.0* |
| Colon and Rectum | 13.1 | -2.3* | Colon and Rectum | 18.7 -1.5 | Colon and Rectum | 16.1 | -1.4* |
| Prostate | 10.1 | -2.3* | Liver \& $1 B^{\text {f }}$ | 13.23 .3 | Liver \& $I^{\text {B }}{ }^{\text {f }}$ | 12.3 | 1.9* |
| Stomach | 8.7 | -3.1* | Pancreas | $10.1 \quad 3.5$ | Pancreas | 9.6 | 0.5 |
| Pancreas | 8.3 | 0.5 | Kidney and Renal Pelvis | 9.50 .1 | Stomach | 7.6 | -2.9* |
| Non-Hodgkin Lymphoma | 5.2 | -2.0* | Stomach | $8.1-5.7 *$ | Non-Hodgkin Lymphoma | 6.5 | -1.4* |
| Leukemia | 5.0 | -0.2 | Leukemia | 7.0 3.7* | Leukemia | 6.1 | -1.1* |
| Esophagus | 3.1 | -1.1 | Esophagus | $6.1-2.4$ | Kidney and Renal Pelvis | 5.1 | -1.5 |
| Oral Cavity and Pharynx | 3.0 | -2.6* | Non-Hodgkin Lymphoma | $5.4-1.8$ | Esophagus | 4.3 | -0.3 |
| Kidney and Renal Pelvis | 3.0 | 3.3* | Urinary Bladder | 4.1 | Urinary Bladder | 4.0 | -1.1 |
| Urinary Bladder | 2.8 | -1.0 | Myeloma | 3.6 -3.6* | Myeloma | 3.5 | -1.9 |
| Brain and ONS ${ }^{\text {f }}$ | 2.3 | -1.5 | Oral Cavity and Pharynx | $3.4-3.4$ | Brain and ONS ${ }^{\text {f }}$ | 3.3 | -0.1 |
| Myeloma | 2.3 | 3.2* | Brain and ONS ${ }^{\text {f }}$ | 2.81 .0 | Oral Cavity and Pharynx | 2.5 | -1.9* |
| Soft Tissue including H | eart 0.9 | 1.2 | Larynx | 2.1 | Larynx | 1.7 | -2.7* |

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Top 15 cancer sites selected based on $2006-2010$ age-adjusted rates for the race/ethnic group. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). The APC is the Annual Percent Change over the time interval.
Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. The 2006-2010 Hispanic death rates do not include deaths from the District of Columbia, North Dakota and South Carolina. The 2001-2010 Hispanic mortality trends do not include deaths from the District of Columbia, Minnesota, New Hampshire, North Dakota and South Carolina.
IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
The APC is significantly different from zero ( $p<.05$ ).
Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

| All Races |  |  | White |  |  | Black |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { Rate }^{b} \\ 2006-2010 \end{gathered}$ | $\begin{gathered} \text { APC }^{\text {C }} \\ 2001-2010 \\ \hline \end{gathered}$ |  | $\begin{gathered} \text { Rate }^{b} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \end{gathered}$ |  | $\begin{gathered} \text { Rate }^{\text {b }} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \\ \hline \end{gathered}$ |
| All Sites | 149.7 | -1.4* | All Sites | 149.8 | -1.3* | All Sites | 171.2 | -1.7* |
| Lung and Bronchus | 39.2 | -0.9* | Lung and Bronchus | 40.4 | -0.8* | Lung and Bronchus | 37.2 | -1.2* |
| Breast | 22.6 | -2.0* | Breast | 22.1 | -2.0* | Breast | 30.8 | -1.6* |
| Colon and Rectum | 13.9 | -3.0* | Colon and Rectum | 13.4 | -3.0* | Colon and Rectum | 19.0 | -3.3* |
| Pancreas | 9.6 | $0.4 *$ | Pancreas | 9.4 | $0.6 *$ | Pancreas | 12.5 | -0.1 |
| Ovary | 8.1 | -1.8* | Ovary | 8.4 | -1.8* | Corpus and Uterus, NOS | 7.4 | $0.7 *$ |
| Leukemia | 5.3 | -1.3* | Leukemia | 5.5 | -1.2* | Ovary | 6.7 | -1.7* |
| Non-Hodgkin Lymphoma | 5.1 | -3.1* | Non-Hodgkin Lymphoma | 5.3 | -3.1* | Myeloma | 5.4 | -2.2* |
| Corpus and Uterus, NOS | 4.3 | 0.5 | Corpus and Uterus, NOS | 4.0 | 0.4 | Leukemia | 4.8 | -1.9* |
| Brain and ONS ${ }^{\text {f }}$ | 3.5 | -0.5* | Brain and ONS ${ }^{\text {f }}$ | 3.8 | -0.4 | Stomach | 4.7 | -3.5* |
| Liver \& $I B D^{\ddagger}$ | 3.4 | 1.6* | Liver \& $1 B^{\text {f }}$ | 3.2 | 1.9* | Cervix Uteri | 4.2 | -2.4* |
| Myeloma | 2.7 | -2.3* | Kidney and Renal Pelvis | 2.6 | -1.2* | Liver \& IBD $^{\ddagger}$ | 4.1 | 0.8 |
| Kidney and Renal Pelvis | 2.6 | -1.3* | Myeloma | 2.5 | -2.3* | Non-Hodgkin Lymphoma | 3.6 | -3.0* |
| Stomach | 2.5 | -2.7* | Urinary Bladder | 2.2 | -0.4 | Urinary Bladder | 2.6 | -1.9* |
| Cervix Uteri | 2.4 | -1.5* | Stomach | 2.2 | -2.7* | Kidney and Renal Pelvis | 2.6 | -1.1* |
| Urinary Bladder | 2.2 | -0.6* | Cervix Uteri | 2.2 | -1.3* | Esophagus | 2.1 | -5.2* |
| Asian/Pacific Islander |  |  | American Indian/Alaska Native ${ }^{\text {d }}$ |  |  | Hispanic ${ }^{\text {e }}$ |  |  |
|  | $\begin{gathered} \text { Rate }^{b} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \\ \hline \end{gathered}$ |  | $\begin{gathered} \text { Rate }^{b} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \\ \hline \end{gathered}$ |  | $\begin{gathered} \text { Rate }^{b} \\ 2006-2010 \\ \hline \end{gathered}$ | $\begin{gathered} \text { APC }^{C} \\ 2001-2010 \\ \hline \end{gathered}$ |
| All Sites | 92.1 | -1.0* | All Sites | 139.0 | -1.1* | All Sites | 101.2 | -1.2* |
| Lung and Bronchus | 18.4 | -0.5 | Lung and Bronchus | 33.1 | -0.8 | Breast | 14.8 | -1.5* |
| Breast | 11.5 | -1.7* | Breast | 15.5 | -1.1 | Lung and Bronchus | 14.1 | -1.1* |
| Colon and Rectum | 9.7 | -1.6* | Colon and Rectum | 15.4 | 0.4 | Colon and Rectum | 10.2 | -2.1* |
| Pancreas | 7.1 | 0.5 | Pancreas | 8.6 | 0.5 | Pancreas | 7.7 | 0.1 |
| Liver \& $1 B^{\text {f }}$ | 6.0 | -1.5 | Ovary | 7.1 | -2.3 | Ovary | 5.8 | -1.2* |
| Stomach | 5.1 | $-3.7 *$ | Liver \& $\mathrm{IBD}^{\text {f }}$ | 6.1 | -1.1 | Liver \& IBD $^{\text {f }}$ | 5.4 | $0.9 *$ |
| Ovary | 4.8 | -0.6 | Kidney and Renal Pelvis | 4.4 | -0.7 | Non-Hodgkin Lymphoma | 4.4 | $-1.5 *$ |
| Non-Hodgkin Lymphoma | 3.4 | -2.0* | Non-Hodgkin Lymphoma | 4.3 | -3.8 | Stomach | 4.4 | -2.6* |
| Leukemia | 3.1 | 0.7 | Stomach | 3.8 | -6.0* | Leukemia | 4.0 | -0.6 |
| Corpus and Uterus, NOS | 2.6 | 2.3* | Cervix Uteri | 3.5 | -0.4 | Corpus and Uterus, NOS | 3.3 | 0.6 |
| Cervix Uteri | 1.9 | -4.6* | Leukemia | 3.3 | -3.4 | Cervix Uteri | 2.9 | -2.3* |
| Brain and ONS ${ }^{\text {f }}$ | 1.6 | 1.6 | Corpus and Uterus, NOS | 3.2 | - | Brain and ONS ${ }^{\text {f }}$ | 2.4 | -0.4 |
| Myeloma | 1.3 | -2.5 | Myeloma | 2.4 | -6.2 | Myeloma | 2.3 | -2.3* |
| Kidney and Renal Pelvis | 1.2 | -0.3 | Brain and ONS ${ }^{\text {f }}$ | 2.3 | - | Kidney and Renal Pelvis | 2.3 | -0.4 |
| Oral Cavity and Pharynx | 1.2 | -2.4 | Gallbladder | 2.0 | -4.6 | Gallbladder | 1.3 | -1.6 |

Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Top 15 cancer sites selected based on 2006-2010 age-adjusted rates for the race/ethnic group. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). The APC is the Annual Percent Change over the time interval.
Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. The 2006-2010 Hispanic death rates do not include deaths from the District of Columbia, North Dakota and South Carolina. The 2001-2010 Hispanic mortality trends do not include deaths from the District of Columbia, Minnesota, New Hampshire, North Dakota and South Carolina.
IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
The APC is significantly different from zero ( $p<.05$ ).
Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

US Mortality 2001-2010
Males by Race/Ethnicity
Prostate


Lung and Bronchus


Colon and Rectum


Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 4.0.3, April 2013, National Cancer Institute.
a Mortality rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.
b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
Mortality data for Hispanics excludes cases from the District of Columbia, Maine, Minnesota, New Hampshire, North Dakota, and Oklahoma.

## US Mortality 2001-2010 Females by Race/Ethnicity



Source: US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 4.0.3, April 2013, National Cancer Institute.
a Mortality rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.
${ }^{\mathrm{b}}$ Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
Mortality data for Hispanics excludes cases from the District of Columbia, Maine, Minnesota, New Hampshire, North Dakota, and Oklahoma.

